2. Academic Validation
  3. Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer

Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer

  • Molecules. 2023 Aug 30;28(17):6343. doi: 10.3390/molecules28176343.
Jian Zhang 1,  Simin Sun 2,  Jinyu Liu 2,  Liang Zhang 2,  Di Guo 1,  Naixin Zhang 3,  Jun Zhao 4,  Dexin Kong 3,  Tongqiang Xu 4,  Xuejian Wang 1,  Wenfang Xu 4 5,  Xiaoyang Li 2 4 5,  Yuqi Jiang 2 4
Affiliations

Affiliations

  • 1 College of Pharmacy, Weifang Medical University, Weifang 261053, China.
  • 2 Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.
  • 3 Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
  • 4 Marine Biomedical Research Institute of Qingdao, Qingdao 266071, China.
  • 5 Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, Qingdao 266237, China.
PMID: 37687169 DOI: 10.3390/molecules28176343
Abstract

The CD13 Inhibitor ubenimex is used as an adjuvant drug with chemotherapy for the treatment of Cancer due to its function as an immunoenhancer, but it has limitations in its cytotoxic efficacy. The Proteasome Inhibitor ixazomib is a landmark drug in the treatment of multiple myeloma with a high anti-cancer activity. Herein, we conjugated the pharmacophore of ubenimex and the boric acid of ixazomib to obtain a dual CD13 and Proteasome Inhibitor 7 (BC-05). BC-05 exhibited potent inhibitory activity on both human CD13 (IC50 = 0.13 μM) and the 20S Proteasome (IC50 = 1.39 μM). Although BC-05 displayed lower anti-proliferative activity than that of ixazomib in vitro, an advantage was established in the in vivo anti-cancer efficacy and prolongation of survival time, which may be due to its anti-metastatic and immune-stimulating activity. A pharmacokinetic study revealed that BC-05 is a potentially orally active agent with an F% value of 24.9%. Moreover, BC-05 showed more favorable safety profiles than those of ixazomib in preliminary toxicity studies. Overall, the results indicate that BC-05 is a promising drug candidate for the treatment of multiple myeloma.

Keywords

CD13 inhibitor; anti-cancer; anti-metastasis; multiple myeloma; proteasome inhibitor.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-149514
    CD13 and Proteasome Inhibitors